Galapagos NV
Research Galapagos NV (GLPG) on Bullrun: market cap USD 1.83B, P/E 4.6. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGLPG
- ExchangeNASDAQ
- CountryBelgium
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.83B
- P/E4.6
- Financial periodQ1 2026
- RevenueUSD 6.48M
- Net incomeUSD 14.49M
- Free cash flow-USD 82.87M
- Gross margin26.0%
Valuation Snapshot
latest market cap is USD 1.83B; P/E is 4.6.
Peer valuation comparison
Latest P/E is 4.65x versus a Healthcare sector median of 24.46x (81.0% below).
Latest P/E is 4.65x versus a Belgium median of 13.16x (64.7% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 1.11B | USD 320.88M | -USD 271.32M | 97.3% | -8.4 | USD 87.87M | USD 6.92M | USD 3.24B |
| FY2024 | USD 275.65M | USD 74.08M | -USD 402.14M | 87.4% | n/a | USD 64.24M | USD 11.72M | USD 2.90B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-05-27 | USD 1.83B | 4.6 | n/a | n/a |
| 2025 | 2025-12-31 | USD 2.15B | 5.5 | n/a | n/a |
| 2024 | 2024-12-31 | USD 1.81B | 22.9 | n/a | n/a |
| 2023 | 2023-12-29 | USD 2.68B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 2.92B | 554.8 | n/a | n/a |
| 2021 | 2021-12-31 | USD 3.61B | n/a | n/a | n/a |
About Galapagos NV
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Galapagos NV's market cap?
Galapagos NV's market capitalization is USD 1.83B.
What is Galapagos NV's P/E ratio?
Galapagos NV's price-to-earnings (P/E) ratio is 4.6.
What does Galapagos NV do?
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.